Antimicrobial and antibiofilm activities of desloratadine against multidrug-resistant Acinetobacter baumannii

Future Microbiol. 2023 Jan:18:15-25. doi: 10.2217/fmb-2022-0085. Epub 2022 Nov 10.

Abstract

Aim: The antimicrobial and antibiofilm activities of the antihistamine desloratadine against multidrug-resistant (MDR) Acinetobacter baumannii were evaluated. Results: Desloratadine inhibited 90% bacterial growth at a concentration of 64 μg/ml. The combination of desloratadine with meropenem reduced the MIC by twofold in the planktonic state and increased the antibiofilm activity by eightfold. Survival curves showed that combinations of these drugs were successful in eradicating all bacterial cells within 16 h. Scanning electron microscopy also confirmed a synergistic effect in imparting a harmful effect on the cellular structure of MDR A. baumannii. An in vivo model showed significant protection of up to 83% of Caenorhabditis elegans infected with MDR A. baumannii. Conclusion: Our results indicate that repositioning of desloratadine may be a safe and low-cost alternative as an antimicrobial and antibiofilm agent for the treatment of MDR A. baumannii infections.

Keywords: Acinetobacter baumannii; antihistamine; biofilm; drug repositioning; multidrug resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acinetobacter baumannii*
  • Anti-Bacterial Agents / pharmacology
  • Anti-Infective Agents* / pharmacology
  • Biofilms
  • Drug Resistance, Multiple, Bacterial
  • Microbial Sensitivity Tests

Substances

  • Anti-Bacterial Agents
  • desloratadine
  • Anti-Infective Agents